RAC1 and neoplasm: Moreover, our results demonstrate that LAPTM5 activates the Jun N-terminal kinase (JNK)/p38 axis by binding to Ras-related C3 botulinum toxin substrate 1 (RAC1), and the effects of LAPTM5 on tumor growth were attenuated following treatment with an RAC1 inhibitor.